(BUSINESS WIRE)--
Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group”), a
biopharmaceutical company focused on the development of novel
therapeutics to address global unmet medical needs, announces the
development of two preclinical drug candidates which target obesity and
neuroblastoma, respectively.
About CLS-1: Treatment of obesity via modulation of chemical signaling relating to gut microbiota
Under
the recently-announced microbiota modulation platform operated by
Aptorum Group’s wholly-owned subsidiary Claves Life Sciences Limited, we
have commenced the preclinical development of macromolecule candidate
CLS-1 targeting the treatment of obesity. CLS-1 is undergoing lead
optimization and is expected to progress into the IND enabling stage in
2020.
The prevalence of obesity continues to escalate globally; however, there is no current optimal therapy for this condition1.
For the majority of obese patients, conventional medical therapies
(i.e., diet, exercise, behavioral counseling) often have a high failure
rate for the long term2. We believe current pharmacotherapy
has limited efficacy and is associated with substantial safety issues,
and this will provide immeasurable market opportunity for CLS-1.
Chemical signaling of gut microbiota is known to be one of the major causes of obesity1.
CLS-1 is an orally administered non-absorbable macromolecule that
modulates the metabolite excreted by gut microbiota with high affinity
and specificity. In this way, we believe the absorption of this
particular metabolite, which is linked to obesity, can be inhibited.
Aptorum
Group is also pursuing two further indications based on the modulation
of microbiota based chemical signaling involving the above large
molecule technology, which we believe to be highly scalable and we hope
to be making further announcements regarding our efforts in due course.
About SACT-1: Repurposed Drug Candidates for the Treatment of Neuroblastoma
Under the recently announced Smart-ACTTM computational
drug discovery platform operated by our wholly-owned subsidiary Smart
Pharma Group, Aptorum Group has completed computational screening of
approximately 1,615 marketed drugs against 3 therapeutic target proteins
to potentially tackle poor prognosis of neuroblastoma, i.e., a rare
type of children’s cancer that forms in certain types of nerve tissue
and most frequently in the adrenal glands as well as spine, chest,
abdomen or neck, especially in children3. For the high-risk
group, the 5-year survival rate of this condition is around 40-50% as
observed by the American Cancer Society.4 Aptorum Group has
identified an array of repurposed candidates and has proceeded to
evaluate them in cell-based and animal models in order to validate the
candidates’ usage for such new indication and potential efficacies.
Aptorum Group is also pursuing two further indications under the Smart-ACTTM drug discovery platform and hopes to be making further announcements regarding our research in due course.
About Aptorum Group Limited
Aptorum
Group Limited (Nasdaq: APM) is a pharmaceutical company dedicated to
developing and commercializing novel therapeutics to tackle unmet
medical needs. Aptorum Group is pursuing therapeutic projects in
neurology, infectious diseases, gastroenterology, oncology and other
disease areas.
For more information about Aptorum Group, please visit www.aptorumgroup.com.
About Claves Life Sciences Limited
Claves
Life Sciences Limited is a wholly-owned therapeutics subsidiary of
Aptorum Group Limited. Claves focuses on the clinical development of
therapeutic candidates related to the field of gastroenterology. The
potential candidates under review and potentially developed focus on the
modulation of gut microbiota-derived metabolites, for the prevention or
treatment of diseases. Claves is also exploring a gut microbiota
modulation platform that can generate novel customized candidates
capable of fine-tuning levels of gut metabolites, potentially treating a
wide range of medical conditions.
About Smart Pharma Group
Smart
Pharma Group includes Smart Pharmaceutical Limited Partnership, SMTPH
Limited and its subsidiaries. The Smart Pharma Group is wholly owned by
Aptorum Group Limited. Smart Pharma Group focuses on systematically
repurposing existing approved drugs for the treatment of a large array
of orphan diseases. Smart Pharma Group conducts both computational based
screening and preclinical validations in advancing the development of
its repurposed candidates.
For more information about Smart Pharma Group, please visit www.smtph.com.
Disclaimer and Forward-Looking Statements
This
press release includes statements concerning Aptorum Group Limited and
its future expectations, plans and prospects that constitute
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. For this purpose, any
statements contained herein that are not statements of historical fact
may be deemed to be forward-looking statements. In some cases, you can
identify forward-looking statements by terms such as “may,” “should,”
“expects,” “plans,” “anticipates,” “could,” “intends,” “target,”
“projects,” “contemplates,” “believes,” “estimates,” “predicts,”
“potential,” or “continue,” or the negative of these terms or other
similar expressions. Aptorum Group has based these forward-looking
statements, which include statements regarding projected timelines for
application submissions and trials, largely on its current expectations
and projections about future events and trends that it believes may
affect its business, financial condition and results of operations.
These forward-looking statements speak only as of the date of this press
release and are subject to a number of risks, uncertainties and
assumptions including, without limitation, risks related to its
announced management and organizational changes, the continued service
and availability of key personnel, its ability to expand its product
assortments by offering additional products for additional consumer
segments, development results, the company’s anticipated growth
strategies, anticipated trends and challenges in its business, and its
expectations regarding, and the stability of, its supply chain, and the
risks more fully described in Aptorum Group’s Form 20-F and other
filings that Aptorum Group may make with the SEC in the future. As a
result, the projections included in such forward-looking statements are
subject to change. Aptorum Group assumes no obligation to update any
forward-looking statements contained in this press release as a result
of new information, future events or otherwise.
|
1 Protein Cell. May; 9(5): 397–403.
2 Obes Surg. 2012 Jun;22(6):956-66
|
Contacts
Investors:
Tel: +852 2117 6611
Email: investor.relations@aptorumgroup.com
Media:
Tel: + 852 2117 6611
Email: info@aptorumgroup.com
No comments:
Post a Comment